EuroIntervention 2012;7:1396-1405

Pre-infarction angina predicts thrombus burden in patients admitted for ST-segment elevation myocardial infarction

Tarek A.N. Ahmed[1,3], MD, PhD; Bastiaan J. Sorgdrager[1], MD; Suzanne C. Cannegieter[2], MD, PhD; Arnoud van der Laarse[1], PhD; Martin J. Schalij[1], MD, PhD; J. Wouter Jukema[1]*, MD, PhD

1. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; 2. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands; 3. Department of Cardiology, Assiut University Hospital, Assiut, Egypt

KEYWORDS

- ST-elevation myocardial infarction
- primary percutaneous coronary intervention
- pre-infarction angina
- thrombus grade
- TIMI flow
- infarct size

Abstract

Aims: In patients with ST-elevation myocardial infarction (STEMI), high thrombotic burden, subsequent distal embolisation and myocardial no-reflow remain a large obstacle that may negate the benefits of urgent coronary revascularisation. We aimed at assessing the predictors of: 1) thrombus grade in patients undergoing primary percutaneous coronary intervention (PPCI) and 2) infarct size, in order to optimise therapy to reduce thrombus burden.

Methods and results: One-hundred and fifty-three consecutive patients presenting with STEMI and undergoing PPCI were included. Thrombus was evaluated by angiography and scored according to the TIMI study group score. Next, patients were categorised into two groups that had either high thrombus grade (HTG; score 4-5) or low thrombus grade (LTG; score 1-3). We evaluated predictors of angiographic thrombus grade among a number of clinical, angiographic and laboratory data. We also assessed infarct size and scintigraphic left ventricular ejection fraction (LVEF) at three months in both patient groups. Ninety-four patients (58±11 years; 75% males) presented with HTG, whereas 59 patients (58±12 years; 78% males) presented with LTG. Pre-infarction angina (PIA) was more frequently encountered in the LTG group than in the HTG group (25% vs. 10%, p=0.009). Pre-procedural TIMI flow was significantly lower in the HTG group (p<0.001), and thrombosuction was more frequently applied in the HTG group (p<0.001). Absence of PIA (OR=0.29, 95% CI=0.11-0.75, p=0.01) and proximal culprit lesion (OR=2.10, 95% CI=1.02-4.36, p=0.04) were the only independent predictors of HTG. HTG proved an independent predictor of higher peak levels of creatine kinase (CK) (p<0.001) and troponin T (p<0.001), as well as lower LVEF (p=0.05) along with male gender and absence of prior statin therapy.

Conclusions: Absence of PIA and proximal culprit lesions are associated with higher thrombus grade. Higher thrombus grade is associated with larger infarct size and slightly worse LV function. This may have clinical implications in planning strategies, particularly regarding pharmacotherapy, that aim to decrease thrombus burden prior to stent implantation.

**Corresponding author: Department of Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: j.w.jukema@lumc.nl*

DOI: 10.4244/EIJV7I12A219

Introduction

Primary percutaneous coronary intervention (PPCI) for patients with ST-segment elevation myocardial infarction (STEMI) aims at early restoration of patency and adequate blood flow both in the epicardial and in the microvascular coronary circulation. However, despite adequate epicardial patency many patients fail to recover sustained myocardial perfusion due to microvascular obstruction[1,2], which carries a prognostic indication of a poor outcome[3,4].

A high thrombotic grade has been shown to predict distal embolisation, and subsequent microvascular obstruction, thus prompting the development of strategies aimed at decreasing thrombus grade before stent deployment such as thrombus aspiration[5] and use of glycoprotein (GP) IIb/IIIa receptor antagonists[6,7].

Pre-infarction angina (PIA) occurring shortly before the onset of acute myocardial infarction (AMI) has a cardioprotective effect due to the mechanism of ischaemic preconditioning[8-10], i.e., the phenomenon by which brief episodes of ischaemia increase the tolerance of the heart to a subsequent major ischaemic insult. Moreover, PIA has been shown to preserve microvascular function after reperfusion[11].

It has been shown that patients with AMI who have intermittent infarct-related pain or unstable angina in the seven days preceding the infarction have faster coronary artery reperfusion and smaller infarcts after thrombolytic therapy than patients without pre-infarction angina, suggesting two different types of thrombus growth and thus different responses to thrombolytic therapy[12]. During PPCI variable grades of thrombus formation are observed that can only be detected on the initial angiography. Ideally it would be possible to predict the thrombus grade clinically or through rapid laboratory investigations prior to PCI procedure. This may help to plan for earlier and enhanced pre-hospital management using adjunctive pharmacotherapy, particularly with the newly emerging rapid-acting reversible antiplatelet agents, which are currently under intense research and are expected to have higher efficacy and safety profiles than the existing treatments.

In this study we aimed to assess factors predicting angiographic thrombotic grade in a consecutive series of patients presenting with STEMI treated by PPCI. In addition, the subsequent infarct size and left ventricular function were assessed among patients with different thrombus grades.

Methods

STUDY POPULATION

We studied 158 consecutive patients with a diagnosis of STEMI, who showed clear evidence of thrombus on the initial angiography, who underwent PPCI and who received abciximab prior to PPCI in the period from 2005-2009. Patients were selected from an ongoing registry (operational since 2004) in Leiden University Medical Center, which evaluates the effects of an all-phase integrated AMI care program (MISSION!) on short- and long-term outcomes[13,14]. Diagnosis of STEMI was made on the basis of typical electrocardiographic changes with clinical symptoms associated with elevation of cardiac biomarkers. All patients were treated according to the institutional AMI protocol (MISSION!). The MISSION! protocol is a rather stringent, rigorously standardised protocol. It comprises a well-organised pre-hospital, in-hospital and outpatient clinical framework for decision-making and treatment, so it is unlikely that procedural changes over time would have influenced the outcomes. Clinical data were prospectively entered into the departmental cardiology information system (EPD-Vision®; Leiden University Medical Center, Leiden, The Netherlands) and retrospectively analysed[13]. The tertiary centre provides a round-the-clock service of PPCI with highly experienced PCI physicians and dedicated nurses.

MEDICATION

All patients received abciximab (Centocor B.V., Leiden, The Netherlands) as a bolus injection of 0.25 mg/kg bodyweight, followed by 0.125 µg/kg/min with a maximum of 10 µg/min as a continuous infusion for 12 hour abciximab administration started before PCI according to MISSION! protocol[13]. Furthermore, all patients received an equivalent of 300 mg of acetylsalicylic acid, 600 mg of clopidogrel as a loading dose before PCI and heparin given as a bolus of 5000 IU at the start of the PCI procedure. After the procedure, all patients received aspirin (75 mg/day) indefinitely and clopidogrel (75 mg/day) for one year. Other medications, including β-blockers, angiotensin-converting enzyme (ACE) inhibitors, nitrates and statins, were prescribed according to MISSION! protocol.

INVASIVE PROCEDURE AND ANGIOGRAPHIC EVALUATION

All PPCI were performed through a 6 Fr femoral sheath. Patients underwent PPCI and stenting of the infarct-related artery according to standard techniques.

The choice of stent (bare metal stent or drug-eluting stent) was left at the operator's discretion. Direct stenting was performed only in cases presenting clear views of the arterial lesion with adequate flow. Otherwise, the patient was subjected to balloon angioplasty and stenting was done subsequently. Thrombectomy was frequently, but not exclusively, performed when high thrombus burden was observed on the initial angiographic image of the target vessel. Thrombus score was graded as previously described by the TIMI study group[6,15]. Briefly, in TIMI thrombus grade 0, no cineangiographic characteristics of thrombus are present; in TIMI thrombus grade 1, possible thrombus is present with such angiographic characteristics as reduced contrast density, haziness, irregular lesion contour, or a smooth convex "meniscus" at the site of total occlusion, suggestive but not diagnostic of thrombus; in TIMI thrombus grade 2, there is definite thrombus, with the greatest dimensions ≤½ the vessel diameter; in TIMI thrombus grade 3, there is definite thrombus but with the greatest linear dimension >½ but <2 times the vessel diameter; in TIMI thrombus grade 4, there is definite thrombus, with the largest dimension ≥2 times the vessel diameter; and in TIMI thrombus grade 5, there is total occlusion. We further categorised the thrombus score into two overall grades: a high thrombus grade (grades 4 and 5), and a low thrombus grade (grades 1-3) **(Figure 1)**. We decided to use this cutoff value in line with pre-



Figure 1. *Thrombus (white arrows) graded according to TIMI working group classification: A) thrombus grade 1; B) thrombus grade 2; C) thrombus grade 3; D) thrombus grade 4; and E) thrombus grade 5; we further scored the thrombus into two overall grades: a high thrombus grade (grades 4 and 5), and a low thrombus grade (grades 1-3).*

vious studies[16-18] that showed the prognostic value of this cutoff. The inter-observer agreement was calculated with weighted Kappa statistics and showed good agreement (κ= 0.92, p<0.001). Coronary flow was graded according to Thrombolysis In Myocardial Infarction (TIMI) criteria[19]. TIMI flow grade was evaluated at baseline and after the PCI procedure.

Procedural success was defined as residual stenosis <20% and TIMI flow grade 3. The coronary angiograms were reviewed offline by two independent interventional cardiologists who were blinded to the clinical data.

LABORATORY INVESTIGATIONS

Cardiac troponin T concentration in plasma was measured on a third generation Elecsys 2010 analyser (Roche Diagnostics, Almere, The Netherlands). Creatine kinase (CK) activity in plasma was measured on a Roche Hitachi Modular P800 analyser (Roche Diagnostics). According to the MISSION! protocol[13] blood samples were collected at admission and every 6 hr in the first 48 hr after PPCI. Subsequently these levels were determined every day up to discharge, unless clinical events prompted repeat measurements. Peak levels of CK and troponin T in plasma were calculated as a measure of infarct size in each patient by an investigator blinded to the assigned treatment.

LVEF ASSESSMENT BY GATED-SPECT

According to the MISSION! protocol[13] all included patients were enrolled for a myocardial perfusion study at 90 days post-PPCI. An ECG-gated single-photon emission computed tomography (SPECT) acquisition at rest using intravenous 99mTechnetium-Tetrofosmin (MYOVIEW™, Amersham, Buckinghamshire, UK) was used to measure the left ventricular ejection fraction (LVEF) 90 days after PPCI. LVEF was calculated using an automated and validated method (QGS software, version 2.0; Cedars-Sinai Medical Center, Los Angeles, CA, USA). Detailed methods are described elsewhere[20]. In patients in whom gated SPECT could not be performed due to technical difficulties, LVEF was estimated by echocardiographic biplane method. LVEF assessment was done by an investigator blinded to the assigned treatment.

DEFINITION OF PRE-INFARCTION ANGINA

Pre-infarction angina (PIA) was defined as at least one episode of typical chest or left arm or jaw pain, either at rest or during exercise, less than seven days before STEMI. The presence of PIA was diagnosed by a physician, blinded to the results of the PCI, from a detailed clinical history taken before PCI.

TESTED VARIABLES

We evaluated predictors of thrombus grade among different clinical, angiographic and laboratory data. Clinical data included age, gender, traditional risk factors, PIA, and symptom to balloon time. Prior pharmacotherapy at admission was also recorded including aspirin, clopidogrel, statins, β-blockers (BB), angiotensin converting enzymes inhibitors or angiotensin receptor blockers (ACEI/ARB). Among laboratory data plasma troponin T levels at admission were recorded. Angiographic data included the culprit artery, location of the culprit lesion, and the number of diseased vessels.

STATISTICAL ANALYSIS

Categorical variables were compared using the X 2 test or Fisher's exact test. Continuous, normally distributed data were tested by Student's t-test or, in the case of a non-Gaussian distribution, by a nonparametric test for independent samples (Mann-Whitney U test).The inter-observer agreements were calculated using weighted Kappa statistics. Variables that at univariate analysis had a p-value ≤0.15 were included in a multiple logistic regression model with the two categories of thrombus grade as the outcome. Infarct size as assessed by peak CK and peak troponin T (after logarithmic transformation), as well as three-months LVEF were analysed in a multivariate linear regression model among different potentially relevant variables. Correlation between the outcomes was tested using Spearman's correlation. Data were expressed as mean±SD, or as median+interquartile range for continuous variables according to the data distribution; categorical variables were expressed as percentages. All analyses were performed using SPSS version 17.0 statistical software (SPSS Inc., Chicago, IL, USA).

Results

BASELINE CHARACTERISTICS

One hundred and fifty-eight consecutive patients were selected for this evaluation. From this group, five patients were excluded due to incomplete data sets, thus the study population comprised 153 patients. Ninety-four patients had high thrombus grade (HTG), and 59 had low thrombus grade (LTG). Baseline clinical and angiographic characteristics of the studied population are presented in **Table 1** and **Table 2**, respectively. The rate of PIA was significantly higher in the LTG group than in the HTG group (25% vs. 10%, p=0.009) **(Figure 2)**. Among the angiographic characteristics, there was less initial TIMI flow grade (p<0.001) and a higher rate of aspiration thrombectomy in the HTG group (p<0.001), than in the LTG group. HTG tended to be more frequently encountered in proximal culprit lesions (54% vs. 39%, p=0.06).

PREDICTORS OF HIGH THROMBUS GRADE (HTG)

Univariate and multivariate logistic regression analyses with thrombus grade as outcome revealed that only absence of PIA (OR=0.29, 95% CI=0.11-0.75, p=0.01) and presence of a proximal culprit lesion (OR=2.10, 95% CI=1.02-4.36, p=0.04) were independent predictors of HTG **(Table 3)**.

Table 1. Baseline clinical characteristics of the study groups.

	HTG n=94	LTG n=59	*p*
Age in years	58.4±11.5	57.6±12.0	0.68[a]
Male, n(%)	70(74.5)	46(78)	0.62[b]
Medical history, n(%)			
Hypertension	28(29.8)	23(39)	0.24[b]
Hyperlipidaemia	21(22.3)	19(32.2)	0.17[b]
Smoking	55(58.5)	28(47.5)	0.18[b]
Family history	43(45.7)	24(40.7)	0.53[b]
Diabetes mellitus	6(6.4)	8(13.6)	0.16[b]
Previous MI	10(10.6)	5(8.5)	0.66[b]
Previous PCI	6(6.4)	5(8.5)	0.62[b]
Previous CABG	4(4.3)	1(1.7)	0.38[b]
Symptoms to balloon (min)	143(95-226)	135(88-225)	0.47[c]
Abciximab to balloon (min)	37(29-48)	36(24-60)	0.95[c]
Pre-infarction angina	9(9.6)	15(25.4)	0.009[b]
Previous aspirin	16(17)	9(15.3)	0.77[b]
Previous clopidogrel	1(1.1)	0(0)	0.42[b]
Previous statins	15(16)	9(15.3)	0.91[b]

Data are presented as mean±standard deviation, number (%) of patients or median (interquartile range); MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; [a] compared using unpaired t test; [b] compared using Chi-square or Fisher exact test; [c] compared using Mann-Whitney U test



Figure 2. *Rate of pre-infarction angina among the two categories of thrombus grade. HTG: high thrombus grade; LTG: low thrombus grade*

INFARCT SIZE

Peak levels of CK and troponin T in plasma were significantly higher in the HTG group than in the LTG group (p<0.001 for both) **(Table 4)**. Among the potentially relevant variables including age, sex, symptom to balloon time, hypertension, current smoking, hypercholesterolaemia, diabetes mellitus, PIA, prior drug therapy, number of diseased vessels, culprit artery, proximal culprit lesion, thrombus grade and use of thrombosuction, HTG predicted high peak levels of CK (B= –1.0, 95% CI= –1.4 - –0.6, p<0.001) and troponin T (B= –1.1, 95% CI=–1.6- –0.6, p<0.001).

Table 2. Angiographic and periprocedural characteristics of the study groups.

	HTG n=94	LTG n=59	*p*
Infarct related artery, n(%)			0.1[a]
Left main artery	3(3.2)	0(0)	
Left anterior descending artery	33(35.1)	24(40.7)	
Circumflex artery	9(9.6)	12(20.3)	
Right coronary artery	49(52.1)	23(39)	
Diseased vessels, n(%)			0.18[a]
1-vessel	57(60.6)	31(52.5)	
2-vessel	33(35.1)	21(35.6)	
3-vessel	4(4.3)	7(11.9)	
Proximal culprit lesion, n(%)	51(54.3)	23(39)	0.06[a]
Abciximab, n(%)	94(100)	58(98.3)	0.9[a]
Initial TIMI flow grade, n(%)			<0.001[a]
0	61(64.9)	16(27.1)	
1	16(17)	12(20.3)	
2	14(14.9)	16(27.1)	
3	3(3.2)	15(25.4)	
Final TIMI flow grade, n(%)			0.16[a]
1	2(2.1)	0(0)	
2	18(19.1)	6(10.2)	
3	74(78.7)	53(89.8)	
Aspiration thrombectomy, n(%)	65(69.1)	13(22)	<0.001[a]
Drug-eluting stents, n(%)	45(57)	52(70)	0.1[a]
Stent number, n(%)			0.25[a]
0	4(4.2)	0(0)	
1	59(62.8)	37(62.7)	
>1	31(33)	22(37.3)	
Predilatation, n(%)	66(70.2)	46(78)	0.29[a]

Data are presented as number (%) of patients; TIMI: Thrombolysis In Myocardial Infarction; [a] compared using Chi-square or Fisher exact test

SCINTIGRAPHIC LVEF AT THREE MONTHS

LVEF was not significantly different between both groups of thrombus grade **(Table 4)**. However, when corrected for the aforementioned factors in a multivariate linear regression model, it was found that HTG predicted a slightly worse LVEF (B=4.9, 95% CI= –0.06-10, p=0.05), along with male gender and absence of prior statin therapy. The outcomes were moderately correlated (r=–0.45, p<0.0001 for LVEF and peak CK; and r= –0.5, p<0.0001 for LVEF and peak TnT).

Discussion

Key findings of the present study were: 1) the absence of PIA and a proximal location of the culprit lesion independently predicted higher angiographic thrombus grade, 2) higher thrombus grade was associated with significantly higher infarct size as assessed by peak CK and troponin T levels in plasma, as well as lower LVEF at three months along with male gender and absence of prior statin therapy.

The issue of identifying predictors of thrombus grade has gained wide interest from the time PPCI was established as the gold standard reperfusion strategy for STEMI. The presence of large thrombus burden has been found to be an independent predictor of major adverse cardiac events (MACE) and infarct-related artery stent thrombosis in patients treated with drug-eluting stents for STEMI[21,22].

CARDIOPROTECTIVE EFFECT OF PIA

PIA is associated with improved prognosis after AMI[9,12,23,24]. Several mechanisms may explain this protective effect of PIA on myocardial reperfusion, such as myocardial ischaemic preconditioning[9,24,25], enhanced collateral circulation towards the ischaemic myocardium[26], and increased sensitivity to thrombolysis[12].

Recently, a new cardioprotective mechanism of PIA was proposed, which is the inhibition of microvascular obstruction phenomenon[27-29]. This was supported by a study conducted by Jesel et al[30], who showed that absence of PIA was the only independent predictor of MRI-detected microvascular obstruction. This provides a new hypothetical mechanism for the clinical benefits of PIA, suggesting that PIA attenuates the development of the no-reflow phenomenon, not only through microvascular ischaemic preconditioning[31], but also through limiting the microvascular obstruction induced by distal embolisation from large thrombus burden. This has to be further elucidated in larger studies reinforced by IVUS or OCT on one hand, and MRI or myocardial contrast echocardiography on the other for relating the extent of culprit plaque morphology and the extent of microvascular obstruction, respectively with PIA.

ANGIOGRAPHIC THROMBUS BURDEN

In 2010, Sianos et al[18] published a score for stratifying thrombus burden in STEMI patients. It was actually a modification from the established TIMI study group score[6], where they reclassified patients with thrombus grade 5 into the other categories. They did that either after crossing with a wire or predilating with a balloon. In our study we adopted the original TIMI classification based on the fact that wire crossing and balloon inflation may alter thrombus grade by inducing distal embolisation. The TIMI study group was precise in defining thrombus grade 5 not only on the basis of total occlusion, but also based on the shape of this total occlusion, which ended abruptly with a squared-off or an upstream convex termination, creating a stump or arterial cul-de-sac from which dye washout was delayed.

PIA AND THROMBUS BURDEN

Our study is the first to address the relation between PIA and thrombus grade in patients with STEMI. Previous studies have shown the benefits of PIA on surrogate markers of reperfusion[29], as well as on clinical outcomes[32].

Using IVUS, Higashikuni et al[33] found that the culprit plaques of patients without PIA contained larger amounts of necrotic core component than patients with PIA, whereas the plaques of patients

Table 3. Univariate and multivariate logistic regression analyses with thrombus grade as endpoint.

Predictors	Univariate analysis			Multivariate analysis		
	OR	95% CI	*p*	OR	95% CI	*p*
Male gender	0.82	0.38-1.78	0.62			
Age	1.01	0.97-1.03	0.68			
Symptom to balloon time	1.00	0.99-1.00	0.72			
Hypertension	1.51	0.76-2.99	0.24			
Hypercholesterolaemia	1.65	0.79-3.43	0.17			
Current smoking	0.64	0.33-1.23	0.18			
Family history	0.81	0.42-1.57	0.54			
Diabetes mellitus	2.30	0.76-7.00	0.14	2.61	0.81-8.39	0.11
Pre-infarction angina	0.31	0.13-0.77	0.01	0.29	0.11-0.75	0.01
Prior aspirin therapy	0.87	0.36-2.14	0.77			
Prior statin therapy	0.95	0.39-2.33	0.91			
Prior ß-blocker therapy	1.29	0.33-5.02	0.71			
Prior ACEI/ARB therapy	1.54	0.70-3.39	0.28			
Infarct related artery‡			0.12			0.17
LAD (including LM)	0.70	0.34-1.44	0.34	0.62	0.29-1.34	0.22
CX	0.35	0.13-0.95	0.04	0.39	0.14-1.11	0.08
Number of diseased vessels*			0.21			
2-vessel disease	0.85	0.42-1.72	0.66			
3-vessel disease	0.31	0.08-1.14	0.08			
Proximal culprit lesion	1.86	0.96-3.60	0.06	2.10	1.02-4.36	0.04
Admission troponin T	1.15	0.59-2.24	0.67			

ACEI/ARB: angiotensin converting enzyme inhibitors/angiotensin receptor blockers; LAD: left anterior descending; CX: circumflex; ‡ right coronary artery (RCA) as reference; * 1-vessel disease as reference

Table 4. Peak CK and troponin T levels and 3-months LVEF in the study groups.

	HTG n=94	LTG n=59	*p*
Peak CK (U/L)	2435±218	1527±234	<0.001[a]
Peak troponin T (µg/L)	6.5±0.7	3.8±0.7	<0.001[a]
LVEF at 3 months*	52±13	54±12	p=0.4[b]

Data are presented as mean ±standard deviation; CK: creatine kinase; LVEF: left ventricular ejection fraction; HTG: high thrombus grade; LTG: low thrombus grade; [a] compared using Mann-Whitney U test; [b] compared using unpaired t test; * computed by Myoview, except in 11% of the patients, where a 2-D echocardiographic biplane method was utilised.

with PIA consisted of larger amounts of the fibro-fatty component than the plaques of patients without PIA. Moreover, they found more plaque rupture among patients without PIA than in those with PIA. This difference may explain the difference in thrombus burden and consequently the difference in clinical outcomes between both groups of patients. The necrotic core component was shown to be the most thrombogenic component in human atherosclerotic plaques[34,35]. Exposure of the necrotic core component (plaque rupture) leads to exposure of tissue factor, thereby increasing thrombogenicity and abrupt thrombus formation. Thus, necrotic core-rich plaques may produce large thrombus burden, which may often result in sudden onset of AMI without PIA. Previously, Kojima et al[36] demonstrated that patients with PIA were more likely to have plaque erosion as a substrate rather than plaque rupture, with subsequent exposure of the proteoglycan-rich matrix without a large lipid core; this has less potent thrombogenicity than plaques with lipid-rich core and consequently leads to less thrombus burden. In a study by Capone et al[37], the incidence of thrombus by angiographic analysis was higher in patients with a recent onset of rest angina than in those with slowly progressive PIA.

PROXIMAL LOCATION OF CULPRIT LESION AND THROMBUS BURDEN

The present study revealed proximal location of the culprit artery as an independent predictor of HTG. To our knowledge, there was one previous study that has addressed this issue[16], revealing no predictive role for the location of the culprit lesion on the thrombus grade. However, in their study they analysed the thrombus in the majority of the cases after the insertion of a 6 Fr perfusion catheter, in contrast to our study in which the thrombus was analysed and graded on the initial angiogram.

The PAMI study[38] showed that patients with proximal culprits had worse angiographic features with higher rates of initial TIMI 0-1 flow, and consequently worse in-hospital clinical outcomes despite rapid and successful reperfusion in the vast majority, thus

arguing for the inclusion of proximal culprit lesion in the angiographic prognostication of AMI patients.

Coronary thromboses leading to AMI are distributed in a non-uniform manner. They tend to cluster within the proximal third of the coronary arteries and the likelihood of clinically significant plaque rupture decreases by 13-30% for each 10 mm distally from the coronary artery ostia[39,40].

THROMBUS BURDEN AND INFARCT SIZE

Our study showed that HTG was a predictor of larger infarct size and when corrected for other relevant risk factors, HTG was associated with a lower LVEF.

Although no previous study has related thrombus grade to infarct size or LVEF, previous studies have shown that distal embolisation and the subsequent no-reflow, which is partly related to higher thrombus burden, were associated with larger infarct size, LV remodelling, and depressed LV function[41,42].

PIA: A PREDICTOR OF INFARCT SIZE?

Although the myocardial protective benefits of PIA have been established in previous studies[10,11,43], we could not reproduce this finding. A possible explanation is that a study with a relatively small sample size (only 24 patients had PIA) lacks statistical power. In a previous study[44], it was concluded that the protective effect of PIA in AMI is overwhelmed by the protective effects of complete revascularisation provided by PPCI.

FUTURE CLINICAL IMPLICATIONS

The present study argues for the consideration of PIA as a clinical predictor of thrombus burden in STEMI patients, thus setting the basis for implementing strategies aiming to decrease thrombus grade before stent implantation such as thrombus aspiration and the use of platelet glycoprotein IIb/IIIa antagonists in selected patients. Earlier administration of IIb/IIIa antagonists results in higher pre-interventional TIMI flow with subsequently improved perfusion post-PCI[45-47], which in turn reflects less thrombus burden. Earlier administration of IIb/IIIa antagonists requires treatment in the pre-hospital setting, which for many dedicated primary PCI centres may pose substantial logistical obstacles. Therefore, the early administration of IIb/IIIa antagonists could be limited to patients in whom high thrombus burden is predicted.

This may set a strategy for pre-hospital triage of STEMI patients receiving early pre-hospital antithrombotic treatment. Since high-dose clopidogrel administration takes 3-4 hr to reach the top of inhibition of platelet aggregation[48], Gp IIb-IIIa inhibitors are considered to more rapidly inhibit platelet aggregation, with subsequent benefits in mortality according to the risk profile. The use of risk scores, such as the TIMI risk score[49], should be strongly encouraged to identify a high risk population with thrombotic complications, which largely outweighs the risk of bleeding complications, and in whom a selective strategy of pre-hospital/pre-PCI aggressive anti-thrombotic therapy is to be adopted.

Recently, a great deal of research has focused on development of new antiplatelet agents that could be administered orally or intravenously and, unlike the currently applied thienopyridines, could provide direct-acting reversible inhibition of the platelet P2Y12 receptor. New agents such as "cangrelor[50-53]" and "elinogrel[54,55]" are characterised by a rapid onset of action, more effective platelet inhibition, and favourable safety profile with rapid reversal of its antiplatelet effect post-infusion, thus allowing for surgery without a significant delay. Furthermore, "vorapaxar" (SCH 530348)[56,57] and "atopaxar" (E5555)[58,59] are orally administered agents that reversibly inhibit platelet protease activated receptor 1 (PAR 1), through which thrombin induces its effect on platelet aggregation, and thus, thrombus formation. This concept of rapid action and rapid reversibility of platelet inhibition could fuel further research about the triage of pre-hospital treatment among STEMI patients with suspected high thrombotic burden.

We believe that the next step towards further optimisation of care among STEMI patients is to improve pre-hospital triage, not only by diagnosing STEMI patients in the ambulance, but also starting early pre-hospital pharmacotherapy which necessitates the implementation of a risk/benefit scoring system. This scoring system should take into consideration clinical (such as PIA), as well as rapid bedside laboratory data (cardiac biomarkers), among other things, to identify patients who would benefit most from early pre-hospital treatment.

Limitations

This study may have been limited by its observational design and the relatively small sample size, which may hinder the prognostic power. However, implementation of a stringent protocol for the study population (MISSION! protocol[13]) reinforces our results. No long-term clinical follow-up was performed. Therefore, a correlation between thrombus burden and clinical outcomes is lacking.

Owing to the small number of included population, and the retrospective nature of the study, we could not perform reliable testing of each single thrombus subgroup. However, Sianos et al[18] validated this categorisation in a large cohort of 900 STEMI patients, and found that large thrombus (≥twice the vessel diameter) independently predicted mortality and MACE.

Many factors can influence the angiographic assessment of thrombus burden (such as the TIMI flow, vessel size, culprit complex lesions with ulcers or intra-plaque dissections that can confuse the analyst). More reliable methods to assess thrombus burden should be considered, such as the amount of aspirated thrombus, or thrombus assessed by optical coherence tomography.

Conclusion

PIA is associated with a decreased angiographic thrombus grade, whereas proximal culprit lesions are associated with higher thrombus grade. Higher thrombus grade was in turn associated with larger infarct size as well as slightly worse LV function. This may have clinical implications in planning strategies, particularly regarding pharmacotherapy, that aim to decrease thrombus burden prior to stent implantation, particularly in high-risk patients without PIA.

Conflict of interest statement

M. Schalij received grants from Eli Lilly, Boston Scientific, Medtronic and Biotronik. All other authors have no conflict of interest to declare.

References

1. Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. *J Am Coll Cardiol.* 2004;44:305-312.

2. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. *Circulation*. 1998;97:765-772.

3. Hombach V, Grebe O, Merkle N, Waldenmaier S, Hoher M, Kochs M, Wohrle J, Kestler HA. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. *Eur Heart J*. 2005;26:549-557.

4. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. *Circulation*. 1996;93:223-228.

5. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. *Lancet*. 2008;371:1915-1920.

6. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. *Circulation*. 2001;103:2550-2554.

7. Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E, Erbs S, Linke A, Mobius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. *Circulation*. 2008;118:49-57.

8. Napoli C, Liguori A, Chiariello M, Di IN, Condorelli M, Ambrosio G. New-onset angina preceding acute myocardial infarction is associated with improved contractile recovery after thrombolysis. *Eur Heart J.* 1998;19:411-419.

9. Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Rusticali F. Prodromal angina limits infarct size. A role for ischemic preconditioning. *Circulation*. 1995;91:291-297.

10. Solomon SD, Anavekar NS, Greaves S, Rouleau JL, Hennekens C, Pfeffer MA. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. *J Am Coll Cardiol.* 2004;43:1511-1514.

11. Colonna P, Cadeddu C, Montisci R, Ruscazio M, Selem AH, Chen L, Onnis E, Meloni L, Iliceto S. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. *Am Heart J.* 2002;144:796-803.

12. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. *N Engl J Med.* 1996;334:7-12.

13. Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J, Viergever EP, van Rees C, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der velde ET, Jukema JW, van der Wall EE, Schalij MJ. MISSION!: Optimization of acute and chronic care for patients with acute myocardial infarction. *Am Heart J.* 2007;153:14.e1-11.

14. van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. *J Am Coll Cardiol*. 2008;51:618-626.

15. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. *Circulation.* 1993;87:38-52.

16. Miranda-Guardiola F, Rossi A, Serra A, Garcia B, Rumoroso JR, Iniguez A, Vaquerizo B, Triano JL, Sierra G, Bruguera J. Angiographic quantification of thrombus in ST-elevation acute myocardial infarction presenting with an occluded infarct-related artery and its relationship with results of percutaneous intervention. *J Interv Cardiol*. 2009;22:207-215.

17. Niccoli G, Spaziani C, Marino M, Pontecorvo ML, Cosentino N, Baca M, Porto I, Leone AM, Crea F. Effect of chronic Aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction. *Am J Cardiol.* 2010;105:587-591.

18. Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. *J Invasive Cardiol.* 2010;22:6B-14B.

19. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. *N Engl J Med*. 1985;312: 932-936.

20. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, Hirai J, Saga T, Yamamoto S, Tonami N. Quantitative rest technetium-99m tetrofosmin imaging in predicting functional recovery after revascularization: Comparison with rest-redistribution thallium-201. *J Am Coll Cardiol.* 1997;29:1226-1233.

21. Burzotta F, Trani C, Romagnoli E, Mazzari MA, Rebuzzi AG, De VM, Garramone B, Giannico F, Niccoli G, Biondi-Zoccai GG, Schiavoni G, Mongiardo R, Crea F. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. *J Am Coll Cardiol.* 2005;46:371-376.

22. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. *J Am Coll Cardiol.* 2007;50:573-583.

23. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, McCabe CH, Braunwald E, TIMI 4 Investigators. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? *Circulation*. 1995;91:37-45.

24. Nakagawa Y, Ito H, Kitakaze M, Kusuoka H, Hori M, Kuzuya T, Higashino Y, Fujii K, Minamino T. Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning". *J Am Coll Cardiol.* 1995;25:1076-1083.

25. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? *J Am Coll Cardiol*. 1994;24:1133-1142.

26. Cribier A, Korsatz L, Koning R, Rath P, Gamra H, Stix G, Merchant S, Chan C, Letac B. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. *J Am Coll Cardiol*. 1992;20:578-586.

27. Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A, Ikushima M, Tanaka K, Kitakaze M, Hori M, Higashino Y, Fujii K. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. *J Am Coll Cardiol.* 2001;38:472-477.

28. Saito T, Kimura K, Kosuge M, Ishikawa T, Endo T, Sugano T, Hibi K, Nakagawa T, Nakatogawa T, Okuda J, Tochikubo O, Umemura S. Relation between the timing of the last preinfarction angina and microvascular reperfusion in patients with recanalized acute myocardial infarction. *Jpn Heart J.* 2003;44:845-854.

29. Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, Mitamura H, Ogawa S. Effect of preinfarction angina pectoris on ST-segment resolution after primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol.* 2002;90: 465-469.

30. Jesel L, Morel O, Ohlmann P, Germain P, Faure A, Jahn C, Coulbois PM, Chauvin M, Bareiss P, Roul G. Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. *Int J Cardiol.* 2007;121:139-147.

31. Dayton C, Yamaguchi T, Warren A, Korthuis RJ. Ischemic preconditioning prevents postischemic arteriolar, capillary, and postcapillary venular dysfunction: signaling pathways mediating the adaptive metamorphosis to a protected phenotype in preconditioned endothelium. *Microcirculation*. 2002;9:73-89.

32. Sejersten M, Birnbaum Y, Ripa RS, Maynard C, Wagner GS, Clemmensen P. Influences of electrocardiographic ischaemia grades and symptom duration on outcomes in patients with acute myocardial infarction treated with thrombolysis versus primary percutaneous coronary intervention: results from the DANAMI-2 trial. *Heart.* 2006;92:1577-1582.

33. Higashikuni Y, Tanabe K, Tanimoto S, Aoki J, Yamamoto H, Nakazawa G, Chihara R, Onuma Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K. Difference of culprit plaque composition between patients with and without pre-infarction angina: an intravascular ultrasound radiofrequency analysis. *EuroIntervention*. 2009;5:363-369.

34. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. *J Am Coll Cardiol.* 1994;23:1562-1569.

35. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. *Circulation*. 1997;95:594-599.

36. Kojima S, Nonogi H, Miyao Y, Miyazaki S, Goto Y, Itoh A, Daikoku S, Matsumoto T, Morii I, Yutani C. Is preinfarction angina related to the presence or absence of coronary plaque rupture? *Heart*. 2000;83:64-68.

37. Capone G, Wolf NM, Meyer B, Meister SG. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. *Am J Cardiol*. 1985;56:403-406.

38. Harjai KJ, Mehta RH, Stone GW, Boura JA, Grines L, Brodie BR, Cox DA, O'Neill WW, Grines CL. Does proximal location of culprit lesion confer worse prognosis in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction? *J Interv Cardiol*. 2006;19:285-294.

39. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. *J Thromb Thrombolysis*. 2003;15:189-196.

40. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. *Circulation*. 2004;110:278-284.

41. Henriques JP, Zijlstra F, Otervanger JP, de Boer MJ, van't Hof AW, Hoorntje JC, Suryapranta H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. *Eur Heart J.* 2002;23:1112-1117.

42. Karila-Cohen D, Czitrom D, Brochet E, Faraggi M, Seknadji P, Himbert D, Juliard JM, Assayag P, Steg PG. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. *Eur Heart J*. 1999;20:1724-1730.

43. Iglesias-Garriz I, Corral F, Rodriguez MA, Garrote C, Montes M, Sevillano E. Pre-infarction angina elicits greater myocardial viability on reperfusion after myocardial infarction: a dobu-

tamine stress echocardiographic study. *J Am Coll Cardiol*. 2001;37:1846-1850.

44. Tomoda H, Aoki N. Comparison of protective effects of pre-infarction angina pectoris in acute myocardial infarction treated by thrombolysis versus by primary coronary angioplasty with stenting. *Am J Cardiol*. 1999;84:621-625.

45. Godicke J, Flather M, Noc M, Gyongyosi M, Arntz HR, Grip L, Gabriel HM, Huber K, Nugara F, Schroder J, Svensson L, Wang D, Zorman S, Montalescot G. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. *Am Heart J*. 2005;150:1015.

46. Hassan AK, Liem SS, van der Kley F, Bergheanu SC, Wolterbeek R, Bosch J, Bootsma M, Zeppenfeld K, van der Laarse A, Atsma DE, Jukema JW, Schalij MJ. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. *Catheter Cardiovasc Interv*. 2009;74:335-343.

47. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). *J Am Coll Cardiol*. 2007;49:1517-1524.

48. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. *Eur Heart J*. 2004;25:1903-1910.

49. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. *Circulation*. 2000;102:2031-2037.

50. Bhatt DL, Harrington RA. A Clinical Trial to Demonstrate the Efficacy of Cangrelor (PCI). National Institutes of Health/Clinicaltrials gov/identifier:NCT00305162. http://www.clinicaltrials.gov/ct2/show/NCT00305162?term=NCT00305162&rank=1.

51. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Jr., Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. *N Engl J Med*. 2009;361:2330-2341.

52. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Jr., Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. *N Engl J Med*. 2009;361:2318-2329.

53. Topol EJ. Maintenance of Platelet Inhibition With Cangrelor (Bridge). National Institutes of Health/Clinicaltrials gov/identifier:NCT00767507. http://www.clinicaltrials.gov/ct2/show/NCT00767507?term=NCT00767507&rank=1 (30 September 2010).

54. A Study to Determine the Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment. National Institutes of Health/Clinicaltrials gov/identifier:NCT00984113. http://www.clinicaltrials.gov/ct2/show/NCT00984113?term=NCT00984113&rank=1 (30 September 2010).

55. Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. *Am Heart J*. 2009;158:998-1004.

56. TRA*CER Executive and Steering Committees: Harrington RA, Van de Werf F, Armstrong PW, Aylward P, Park B, Veltri E, Mahaffey KW, Moliterno DJ, Strony J, Wallentin L, White HD, Diaz R, Aylward P, Huber K, Van de Werf F, Nicolau JC, Armstrong PW, Prieto JC, Isaza D, Widimsky P, Grande P, Nieminen M, Montalescot G, Bode C, Wong L, Ofner P, Lewis BS, Ambrosio G, Valgimigli M, Ogawa H, Yamaguchi T, Jukema JW, Cornel JH, White HD, Nordrehaug JE, Ruzyllo W, Providencia L, Tan HC, Dalby A, Seung-Jung P, Betriu A, Cequier A, Held C, Pfisterer M, Chen MF, Timurkaynak T, Storey RF, Chen E, Harrington RA, Hudson MP, Lincoff AM, Mahaffey KW, Morrow DA, Tricoci P, Whellan D. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. *Am Heart J*. 2009;158:327-334.

57. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. *Am Heart J*. 2009;158:335-341.

58. A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease. National Institutes of Health/Clinicaltrials gov/identifier:NCT00540670. http://www.clinicaltrials.gov/ct2/show/NCT00540670?term=NCT00540670&rank=1 (30 September 2010).

59. A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome. National Institutes of Health/Clinicaltrials gov/identifier:NCT00619164. http://www.clinicaltrials.gov/ct2/show/NCT00619164?term=NCT00619164&rank=1 (30 September 2010).